Jeroen A. Hendrikx
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: May 19, 2026
Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review.
Journal: Cancer chemotherapy and pharmacology
Published: April 29, 2026
Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 10, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: March 12, 2026
PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 12, 2026
Oncological Outcomes of Robot-assisted PSMA-guided Salvage Surgery in Recurrent Prostate Cancer: Insights from the Prospective TRACE-I Trial.
Journal: European urology focus
Published: January 24, 2026
Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [177Lu]Lu-PSMA-I&T.
Journal: EJNMMI radiopharmacy and chemistry
Published: October 03, 2025
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: October 01, 2025
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.
Journal: Clinical pharmacokinetics
Published: October 01, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.
Journal: Clinical pharmacokinetics
Published: July 14, 2025
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.
Journal: Journal for immunotherapy of cancer
Published: July 05, 2025
Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 02, 2025
Last Updated: 09/26/2026